The IDR system has added at least $5 billion to overall health system costs since its inception, prompting the question of ...

The purpose of leveraging wearables is to promote better outcomes. Model tests offer a way to link reimbursement to ...

Even if data are removed from a system, it’s possible that an AI model may still be retaining the ‘lessons’ it learned from ...

The One Big Beautiful Bill Act created exemptions and delays to the negotiation of orphan drugs, which are poised to erode savings from negotiation by more than previous analyses suggested.

While the law has successfully protected consumers from the most common types of surprise out-of-network bills, its ...

State cost growth targets—when paired with complementary strategies such as site-neutral payment policies, price growth caps, prescription drug price and pharmacy benefit manager oversight, and ...

By broadening the orphan drug exclusion and delaying eligibility until a non-orphan indication is approved, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act has effectively redrawn the ...

Creating clear regulatory frameworks and reimbursement standards can help ensure the responsible and effective integration of ...

The threat to disparate impact analysis places our country at a crossroads. One path leads to public health scholarship and ...

By focusing on three priorities—one corresponding to each goal—the Center for Medicare and Medicaid Innovation’s leaders can ...

Recently, the Second Circuit, Sixth Circuit, and a Texas district again rejected the pharmaceutical industry’s challenges to ...

Our national action plan to strengthen support for informal caregivers would provide resources needed to sustain their ...